Theravance Biopharma (TBPH) Misses Q2 EPS by 1c

Theravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($1.06), $0.01 worse than the analyst estimate of ($1.05).

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• St. James's Place plc (STJ:LN) (STJPF) PT Raised to GBP20.50 at Deutsche Bank